2014 Update of the drug resistance mutations in HIV-1
| Autor: | Wensing, Annemarie M., Calvez, Vincent, Huldrych Günthard, Johnson, Victoria A., Paredes, Roger, Pillay, Deenan, Shafer, Robert W., Richman, Douglas D. |
|---|---|
| Přispěvatelé: | University of Zurich |
| Rok vydání: | 2014 |
| Předmět: |
Anti-HIV Agents
Mutation Missense Drug Resistance virus diseases 610 Medicine & health HIV Infections 2725 Infectious Diseases 10234 Clinic for Infectious Diseases 3004 Pharmacology immune system diseases Drug Resistance Viral Mutation 2406 Virology HIV-1 2736 Pharmacology (medical) Humans Point Mutation Viral Missense |
| Zdroj: | Topics in antiviral medicine, vol 22, iss 3 ResearcherID Wensing, Annemarie M; Calvez, Vincent; Günthard, Huldrych F; Johnson, Victoria A; Paredes, Roger; Pillay, Deenan; et al.(2014). 2014 Update of the drug resistance mutations in HIV-1.. Topics in Antiviral Medicine, 22(3), 642-650. UC Office of the President: Research Grants Program Office (RGPO). Retrieved from: http://www.escholarship.org/uc/item/6sk1h27j |
| Popis: | This July 2014 edition of the IAS-USA drug resistance mutations list updates the figures last published in March 2013. The following mutations have been added to existing classes or drugs: K65E/N has been added to the bars for the nucleoside and nucleotide analogue reverse transcriptase inhibitors (nRTIs) abacavir, didanosine, emtricitabine, lamivudine, stavudine, and tenofovir; L100I has been added to the bar for the nonnucleoside analogue reverse transcriptase inhibitor (NNRTI) rilpivirine; and F121Y has been added to the bars for the integrase strand transfer inhibitors (InSTIs) dolutegravir, elvitegravir, and raltegravir. With regard to protease inhibitors (PIs), it cannot be excluded that drug resistance may be selected for outside the protease encoding region. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|